Diabetes and Metabolic Disorders: The Approval of Teplizumab
Teplizumab, the first disease-modifying therapy for Type 1 diabetes, delays disease onset by ~4 years in high-risk individuals. Priced at $194,000 per course, it redefines early intervention despite cost barriers.
June 23, 2025
by David Orchard-Webb
The Transformative Role of Blockchain in the Pharmaceutical Industry
The pharmaceutical business, long considered one of the most regulated and difficult sectors, is experiencing a digital transition.
April 21, 2025
by David Orchard-Webb
Recent Updates on the Guidelines to Clinical Trials through Innovations
The CDER Center for Clinical Trials Innovation (C3TI) was recently created by the FDA's Center for Drug Evaluation and Research (CDER) to facilitate and expand novel approaches to clinical trials intended to increase the effectiveness of drug development.
January 15, 2025
by Shruti Talashi
Echinacea Extract: Therapeutic Potential and Traditional Uses
Echinacea is known for its brilliant purple petals and cone-shaped core, has been used for generations for medicinal purposes.
November 5, 2024
by David Orchard-Webb
The Transformative Role of Generative AI (genAI) in the Pharmaceutical Industry
The future of genAI in pharmaceuticals is bright, promising a healthier, more efficient approach to drug development and patient care.
April 1, 2024
by David Orchard-Webb
Vetter Earns Prestigious Honors Across All Core Categories in the 13th Annual CDMO Leadership Awards
Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma, small pharma and overall respondents.
March 27, 2024
by PharmaSources
Why Diverse Representation in Clinical Research Matters
Randomised controlled trials (RCTs), where study participants are randomly allocated to an experimental group or a control group, became the ‘gold standard’ of clinical research in the mid-20th century.
March 19, 2024
by Suzanne Elvidge
Understanding clinical trials in approval of novel medication into the health market
The first step in creating a new medication is to gain as much knowledge as you can about the illness or condition. Basic research offers hints about prospective treatment approaches for illnesses, including addressing their symptoms or underlying causes.
December 1, 2023
by Shruti Talashi
Breakthroughs in Melanoma Immunotherapy & RNA Vaccines
Melanoma is a type of skin cancer that develops from pigment-producing cells called melanocytes.
July 3, 2023
by Daivd Orchard Webb/PharmaSources
The Dynamic Diabetes and Metabolic Disorder Treatment Landscape
Diabetes is a chronic medical condition characterized by high levels of glucose in the blood.
July 3, 2023
by Daivd Orchard Webb/PharmaSources
First-in-Human Clinical Data Shows SonoTran® is Safe and Well-Tolerated
OxSonics Therapeutics, announces that first-in-human clinical data demonstrated that SonoTran® is safe and well-tolerated, with consistent Particle activation observed and mapped using OxSonics’ proprietary “see-as-you-treat” technology.
January 23, 2023
by PharmaSources
Weekly Pharma News Review | PharmaSources.com (May.6th to May.15th)
The most encouraging news this week is that the international, multicenter, Phase III clinical trials of Hengrui's PD-1 combination therapy for liver cancer have been announced to be successful.
May 18, 2022
by PharmaSources.com